Search
Bausch + Lomb Corp
BLCOAdd to Watchlist
17.160USD
-0.160-0.92%
Market hours 09/23, 11:39（ET）
6.13BMarket Cap
LossP/E TTM
About Bausch + Lomb Corp Company
Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
Bausch + Lomb Corp Profile
Ticker SymbolBLCO
Company nameBausch + Lomb Corp
IPO dateMay 06, 2022
CEOSaunders (Brenton L)
Number of employees13500
Security typeOrdinary Share
Fiscal year-endMay 06
Address520 Applewood Crescent
CityVAUGHAN
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountryCanada
Postal codeL4K 4B4
Phone19082552864
Websitehttps://ir.bausch.com/
Ticker SymbolBLCO
IPO dateMay 06, 2022
CEOSaunders (Brenton L)
Company Executives of Bausch + Lomb Corp
Name
Name/Position
Position
Shareholding
Change
Mr. Luc Bonnefoy
Mr. Luc Bonnefoy
President - Surgical
President - Surgical
103.80K
+16.16%
Mr. Luc Bonnefoy
Mr. Luc Bonnefoy
President - Surgical
President - Surgical
103.80K
+16.16%
Dr. Yehia Hashad, M.D.
Dr. Yehia Hashad, M.D.
Executive Vice President - Research & Development, Chief Medical Officer
Executive Vice President - Research & Development, Chief Medical Officer
93.77K
+22.37%
Dr. Yehia Hashad, M.D.
Dr. Yehia Hashad, M.D.
Executive Vice President - Research & Development, Chief Medical Officer
Executive Vice President - Research & Development, Chief Medical Officer
93.77K
+22.37%
Karen Ling ,
Karen Ling ,
Independent Director
Independent Director
57.52K
+62.90%
Mr. Russel C. Robertson
Mr. Russel C. Robertson
Independent Director
Independent Director
27.66K
+57.27%
Mr. Russel C. Robertson
Mr. Russel C. Robertson
Independent Director
Independent Director
27.66K
+57.27%
Mr. Thomas J. Appio
Mr. Thomas J. Appio
Chairman of the Board
Chairman of the Board
27.58K
--
Mr. Thomas J. Appio
Mr. Thomas J. Appio
Chairman of the Board
Chairman of the Board
27.58K
--
Mr. Sam A. Eldessouky
Mr. Sam A. Eldessouky
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Luc Bonnefoy
Mr. Luc Bonnefoy
President - Surgical
President - Surgical
103.80K
+16.16%
Mr. Luc Bonnefoy
Mr. Luc Bonnefoy
President - Surgical
President - Surgical
103.80K
+16.16%
Dr. Yehia Hashad, M.D.
Dr. Yehia Hashad, M.D.
Executive Vice President - Research & Development, Chief Medical Officer
Executive Vice President - Research & Development, Chief Medical Officer
93.77K
+22.37%
Dr. Yehia Hashad, M.D.
Dr. Yehia Hashad, M.D.
Executive Vice President - Research & Development, Chief Medical Officer
Executive Vice President - Research & Development, Chief Medical Officer
93.77K
+22.37%
Karen Ling ,
Karen Ling ,
Independent Director
Independent Director
57.52K
+62.90%
Mr. Russel C. Robertson
Mr. Russel C. Robertson
Independent Director
Independent Director
27.66K
+57.27%
FAQs
Who are the top five shareholders of Bausch + Lomb Corp?
The top five shareholders of Bausch + Lomb Corp are: Mr. Luc Bonnefoy
How many institutions hold shares of Bausch + Lomb Corp (BLCO)?
As of 2026Q1, 249 institutions hold shares of Bausch + Lomb Corp, with a combined market value of approximately 40.30M, accounting for 11.30% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -25007155.00.
What is the biggest source of revenue for Bausch + Lomb Corp?
In 2026Q1, the Devices business generated the highest revenue for Bausch + Lomb Corp, amounting to 524.00M and accounting for 37.59% of total revenue.